How the WHO hepatitis strategy measures up in the field
How direct-acting antivirals are transforming treatment of hepatitis C.
Access and elimination: the future of DAAs in hepatitis C
Gilead has led a revolution in curing hepatitis C, but now faces a slowdown.
Many millions still untreated – but hep C boom is already over
European safety experts review latest hepatitis C drugs
Hepatitis C: breaking down the stigma
AbbVie aiming to steal market share from Gilead
AbbVie’s hep C combination approved in Europe